Triazolopyridazine LRRK2 kinase inhibitors

被引：24

作者：

Franzini, Maurizio ^{[1
]}

Ye, Xiaocong M. ^{[1
]}

Adler, Marc ^{[2
]}

Aubele, Danielle L. ^{[1
]}

Garofalo, Albert W. ^{[1
]}

Gauby, Shawn ^{[3
]}

Goldbach, Erich ^{[3
]}

Probst, Gary D. ^{[1
]}

Quinn, Kevin P. ^{[3
]}

Santiago, Pam ^{[3
]}

Sham, Hing L. ^{[1
]}

Tam, Danny ^{[4
]}

Anh Truong ^{[1
]}

Ren, Zhao ^{[4
]}

机构：

[1] Elan Pharmaceut, Dept Med Chem, San Francisco, CA 94080 USA

[2] Elan Pharmaceut, Dept Mol Design, San Francisco, CA 94080 USA

[3] Elan Pharmaceut, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA

[4] Elan Pharmaceut, Dept Assay Dev, San Francisco, CA 94080 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2013年 / 23卷 / 07期

关键词：

LRRK2; Parkinson's; Inhibition; Kinase; Treatment; Discovery; Wild-type; G2019S mutant; Phosphorylation; SAR; Activity; Selectivity; Bioisostere; Hinge; HTS; Oxidative metabolism; Binding mode; Synthesis; CENTER-DOT-LICL; PARKINSONS-DISEASE; HETEROAROMATICS; AROMATICS; ZINCATION; TARGETS; BINDING;

D O I：

10.1016/j.bmcl.2013.02.043

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Leucine-rich repeat kinase 2 (LRRK2) has been implicated in the pathogenesis of Parkinson's disease (PD). Inhibition of LRRK2 kinase activity is a therapeutic approach that may lead to new treatments for PD. Herein we report the discovery of a series of [1,2,4]triazolo[4,3-b]pyridazines that are potent against both wild-type and mutant LRRK2 kinase activity in biochemical assays and show an unprecedented selectivity towards the G2019S mutant. A structural rational for the observed selectivity is proposed. (C) 2013 Elsevier Ltd. All rights reserved.

引用

下载

页码：1967 / 1973

页数：7

共 50 条

[31] Inhibition of LRRK2 kinase activity stimulates macroautophagy
Manzoni, Claudia
Mamais, Adamantios
Dihanich, Sybille
Abeti, Rosella
Soutar, Marc P. M.
Plun-Favreau, Helene
Giunti, Paola
Tooze, Sharon A.
Bandopadhyay, Rina
Lewis, Patrick A.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2013, 1833 (12): : 2900 - 2910
[32] Inhibitors of LRRK2 as Treatment for Parkinson's Disease
Abdel-Magid, Ahmed F.
ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 701 - 702
[33] Role of LRRK2 kinase dysfunction in Parkinson disease
Kumar, Azad
Cookson, Mark R.
EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 : e20
[34] Discovery of novel thienopyrimidine derivatives as LRRK2 inhibitors
Choi, Changyu
Park, Jiwon
Jang, Soyeon
Kim, Jihyung
Lee, Sohee
Min, Kyung Hoon
BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2022, 43 (02) : 232 - 235
[35] Interaction of LRRK2 with kinase and GTPase signaling cascades
Boon, Joon Y.
Dusonchet, Julien
Trengrove, Chelsea
Wolozin, Benjamin
FRONTIERS IN MOLECULAR NEUROSCIENCE, 2014, 7
[36] Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission
Qin, Qi
Zhi, Lian-Teng
Li, Xian-Ting
Yue, Zhen-Yu
Li, Guo-Zhong
Zhang, Hui
CNS NEUROSCIENCE & THERAPEUTICS, 2017, 23 (02) : 162 - 173
[37] LRRK2 and ubiquitination: implications for kinase inhibitor therapy
Melrose, Heather L.
BIOCHEMICAL JOURNAL, 2015, 470 : E21 - E24
[38] LRRK2: from kinase to GTPase to microtubules and back
Blanca Ramirez, Marian
Lara Ordonez, Antonio Jesus
Fdez, Elena
Hilfiker, Sabine
BIOCHEMICAL SOCIETY TRANSACTIONS, 2017, 45 : 141 - 146
[39] Rab GTPases as Physiological Substrates of LRRK2 Kinase
Seol, Wongi
Nam, Daleum
Son, Ilhong
EXPERIMENTAL NEUROBIOLOGY, 2019, 28 (02) : 134 - 145
[40] Biogen licenses Denali's LRRK2 inhibitors
Jarvis, Lisa M.
CHEMICAL & ENGINEERING NEWS, 2020, 98 (31) : 12 - 12

← 1 2 3 4 5 →